tetano
Editor, Senior Moderator
Nat Commun
. 2026 Jan 13;17(1):434.
doi: 10.1038/s41467-025-64829-6. Intranasal replicon vaccine establishes mucosal immunity and protects against H5N1 and H7N9 influenza
Matthew R Ykema[SUP] 1 [/SUP], Michael A Davis[SUP] 1 [/SUP], Darshan N Kasal[SUP] 1 [/SUP], Madeleine F Jennewein[SUP] 1 [/SUP], Ethan Lo[SUP] 1 [/SUP], Jasneet Singh[SUP] 1 [/SUP], Samuel Beaver[SUP] 1 [/SUP], Noah Cross[SUP] 1 [/SUP], Eduard Melief[SUP] 1 [/SUP], Sierra Reed[SUP] 1 [/SUP], Christopher Press[SUP] 1 [/SUP], Devin S Brandt[SUP] 1 [/SUP], Wynton D McClary[SUP] 1 [/SUP], Raodoh Mohamath[SUP] 1 [/SUP], Pauline Fusco[SUP] 1 [/SUP], Julie Bakken[SUP] 1 [/SUP], Corey Casper[SUP] 1 2 3 4 [/SUP], Airn Tolnay Hartwig[SUP] 5 [/SUP], Alana Gerhardt[SUP] 1 [/SUP], Richard A Bowen[SUP] 5 [/SUP], Emily A Voigt[SUP] 6 7 [/SUP]
Affiliations
Seasonal and pandemic influenza viruses are continuous threats to human health, requiring rapid development of vaccines to multiple evolving viral strains. RNA vaccine technologies have the adaptability and manufacturability to facilitate pandemic preparedness but have limited flexibility in their route of administration, reducing the ability to establish local protective immune responses such as respiratory mucosal immunity. Here, we describe monovalent and bivalent replicon vaccines against A/Vietnam/1203/2004 H5N1 and A/Anhui/PA-1/2013 H7N9. These replicon vaccines express either H5 or H7 hemagglutinin and are formulated with a nanostructured lipid carrier (NLC) that permits both intramuscular (IM) and intranasal (IN) dosing. In mice, IM vaccination established systemic humoral and cellular responses but no detectable mucosal response, while IN administration induced robust systemic and mucosal immunity. The replicon-NLC vaccines protected against morbidity and mortality in ferret challenge models, establishing this intranasally-administered replicon-NLC vaccine platform as a potential pandemic response tool.
. 2026 Jan 13;17(1):434.
doi: 10.1038/s41467-025-64829-6. Intranasal replicon vaccine establishes mucosal immunity and protects against H5N1 and H7N9 influenza
Matthew R Ykema[SUP] 1 [/SUP], Michael A Davis[SUP] 1 [/SUP], Darshan N Kasal[SUP] 1 [/SUP], Madeleine F Jennewein[SUP] 1 [/SUP], Ethan Lo[SUP] 1 [/SUP], Jasneet Singh[SUP] 1 [/SUP], Samuel Beaver[SUP] 1 [/SUP], Noah Cross[SUP] 1 [/SUP], Eduard Melief[SUP] 1 [/SUP], Sierra Reed[SUP] 1 [/SUP], Christopher Press[SUP] 1 [/SUP], Devin S Brandt[SUP] 1 [/SUP], Wynton D McClary[SUP] 1 [/SUP], Raodoh Mohamath[SUP] 1 [/SUP], Pauline Fusco[SUP] 1 [/SUP], Julie Bakken[SUP] 1 [/SUP], Corey Casper[SUP] 1 2 3 4 [/SUP], Airn Tolnay Hartwig[SUP] 5 [/SUP], Alana Gerhardt[SUP] 1 [/SUP], Richard A Bowen[SUP] 5 [/SUP], Emily A Voigt[SUP] 6 7 [/SUP]
Affiliations
- PMID: 41530119
- DOI: 10.1038/s41467-025-64829-6
Seasonal and pandemic influenza viruses are continuous threats to human health, requiring rapid development of vaccines to multiple evolving viral strains. RNA vaccine technologies have the adaptability and manufacturability to facilitate pandemic preparedness but have limited flexibility in their route of administration, reducing the ability to establish local protective immune responses such as respiratory mucosal immunity. Here, we describe monovalent and bivalent replicon vaccines against A/Vietnam/1203/2004 H5N1 and A/Anhui/PA-1/2013 H7N9. These replicon vaccines express either H5 or H7 hemagglutinin and are formulated with a nanostructured lipid carrier (NLC) that permits both intramuscular (IM) and intranasal (IN) dosing. In mice, IM vaccination established systemic humoral and cellular responses but no detectable mucosal response, while IN administration induced robust systemic and mucosal immunity. The replicon-NLC vaccines protected against morbidity and mortality in ferret challenge models, establishing this intranasally-administered replicon-NLC vaccine platform as a potential pandemic response tool.